Improvement in Tardive Dyskinesia After Muscimol Therapy

C. A. Tamminga, J. W. Crayton, T. N. Chase

Research output: Contribution to journalArticlepeer-review

96 Scopus citations


Muscimol, thought to be a agonist of γ-aminobutyric acid (GABA), was administered to eight neuroleptic-free subjects with tardive dyskinesia. At oral dose levels from 5 to 9 mg, involuntary movements were consistently attenuated, usually in the absence of sedation. These results support the view that pharmacologic attempts to stimulate GABA-mediated synaptic transmission may afford symptomatic relief to patients with tardive dyskinesia.

Original languageEnglish (US)
Pages (from-to)595-598
Number of pages4
JournalArchives of General Psychiatry
Issue number5
StatePublished - May 1979

ASJC Scopus subject areas

  • Arts and Humanities (miscellaneous)
  • Psychiatry and Mental health


Dive into the research topics of 'Improvement in Tardive Dyskinesia After Muscimol Therapy'. Together they form a unique fingerprint.

Cite this